visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Recombinant pharmaceuticals from microbial cells : |
Data: | 2016 |
Resum: | Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or malfunction. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional proteins produced ex vivo is required. As both protein extraction from natural producers and chemical synthesis undergo inherent constraints that limit regular large-scale production, recombinant DNA technologies have rapidly become a choice for therapeutic protein production. The spectrum of organisms exploited as recombinant cell factories has expanded from the early predominating Escherichia coli to alternative bacteria, yeasts, insect cells and especially mammalian cells, which benefit from metabolic and protein processing pathways similar to those in human cells. Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by recombinant technologies. Other 1300 recombinant pharmaceuticals are under development, with a clear tendency towards engineered versions with improved performance and new functionalities regarding the conventional, plain protein species. This trend is exemplified by the examination of the contemporary protein-based drugs developed for cancer treatment. |
Ajuts: | Ministerio de Economía y Competitividad BIO2013-41019P Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-132 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/PROD-00055 Ministerio de Economía y Competitividad PI12/00327 Ministerio de Economía y Competitividad PI15/00272 Ministerio de Economía y Competitividad PI15/00378 |
Nota: | Altres ajuts: MARATÓ TV3: 2013-3930, 2013-132031 |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Recombinant proteins ; Protein drugs ; Recombinant DNA ; Fusion proteins ; Biopharmaceuticals |
Publicat a: | Microbial cell factories, Vol. 15, Issue 33 (February 2016) , ISSN 1475-2859 |
7 p, 1.2 MB |